Clinical trial NCT02157324: Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
Official title: A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination With ACP-319 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Chronic Lymphocytic Leukemia
Keywords: Bruton tyrosine kinase inhibitor
Btk
Lead sponsor: Acerta Pharma BV
Sponsor class: INDUSTRY
First posted: 2014-06-06
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)


Eligibility criteria: Inclusion Criteria:

* Men and women ≥ 18 years of age with a confirmed diagnosis of CLL, which has relapsed after, or been refractory to, ≥ 1 previous treatments for CLL; however, subjects with 17p deletion are eligible if they have relapsed after, or been refractory to, 1 prior treatment for CLL.
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
* Agreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.

Exclusion Criteria:

* Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to \< 2 years.
* A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib and/or ACP-319, or put the study outcomes at undue risk.
* Significant cardiovascular disease.
* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
* Any immunotherapy within 4 weeks of first dose of study drug.
* For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after 5 times the half-life of the agent(s).
* History of prior allogeneic bone marrow progenitor cell or solid organ transplantation.
* Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids for treatment of CLL or other conditions. Note: Subjects may be using topical or inhaled corticosteroids as therapy for comorbid conditions.
* Central nervous system (CNS) involvement by CLL.
* Grade ≥ 2 toxicity (other than alopecia).
* Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection.
* Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.
* Absolute neutrophil count (ANC) \< 0.75 x 109/L or platelet count \< 50 x 109/L unless due to disease involvement in the bone marrow.
* Creatinine \> 1.5 x institutional upper limit of normal (ULN); total bilirubin \> 1.5 x ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 x ULN unless disease related.
* Significant screening ECG abnormalities including left bundle branch block, 2nd degree AV block type II, 3rd degree block, Grade 2 or higher bradycardia, and QTc \> 480 msec.

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events
timeFrame: From date of randomization until the day of documented progression or date of death from any cause, whichever came first, assessed up to 60 cycles of 28 days.
Secondary outcomes:
measure: Drug Exposure, Area Under the Plasma Concentration-time Curve
timeFrame: From 30 min before first dose to day-28 of cycle-6 of a 28 day cycle
measure: Drug Exposure, Maximum observed plasma concentration
timeFrame: From 30 min before first dose to 30 min before day-28 of cycle-6 of 28 day cycles
measure: Drug Exposure, Time of the maximum plasma concentration
timeFrame: From 30 min before first dose till 30 before day-28 of cycle-6 of 28 day cycles
measure: Overall Response rate
timeFrame: Pretreatment, then end of cycles 2, 4, 9, 12, 18 and then every 6 cycles to cycle 36. After that at cycle 48 and 60 of 28 day cycles.
measure: Duration of Response
timeFrame: Pretreatment, then end of cycles 2, 4, 9, 12, 18 and then every 6 cycles to cycle 36. After that at cycle 48 and 60 of 28 day cycles.
measure: Progression-Free Survival
timeFrame: Pretreatment, then end of cycles 2, 4, 9, 12, 18 and then every 6 cycles to cycle 36. After that at cycle 48 and 60 of 28 day cycles.
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Research Site
state: Ohio
city: Hermitage
country: United States
facility: Research Site
state: Tennessee
city: Fort Worth
country: United States
facility: Research Site
state: Texas
Study officials:
affiliation: 1-888-292-9613 acertamc@dlss.com
name: Acerta Clinical Trials
role: STUDY_DIRECTOR
References: